Effective and targeted delivery

Futura has developed a highly efficient and proprietary drug delivery technology platform, DermaSys®, which is designed to drive more active compound through the skin. DermaSys® offers a versatile delivery profile that can be tailored to suit a specific active compound and therapeutic indication. Futura's unique DermaSys® technology enables targeted and rapid delivery of active pharmaceutical ingredients (API) through the skin to the required site of action.

For our erectile dysfunction treatment, MED2005, this translates into a fast onset of action and rapid clearance, with the potential for MED2005 to be the fastest-acting treatment for erectile dysfunction with a favourable safety profile.

MED2005 uses unique DermaSys® technology, which enables targeted and rapid delivery of GTN through the tissue to achieve and maintain an erection

Comparative pharmacokinetics - MED2005 is rapidly absorbed with potential for prolonged action compared with leading PDE5i's chart

 

For our pain relief treatments, TPR100 and TIB200, this translates into a fast onset of action and long lasting pain relief, with the potential for improved patient benefit by reducing the dosing frequency to twice daily. The graph below shows how TPR100 works.

Futura's unique DermaSys® technology enables targeted delivery of ibuprofen through the skin to the site of action and sustained release.

TPR100 Diagram

Strong IP and product differentiation

DermaSys® is a proprietary drug delivery technology platform with very strong IP offering a high level of product differentiation compared to existing marketed treatments. The use of well characterised generic molecules translates into a lower development risk and potentially a shorter regulatory pathway.